Cargando…

HER2/neu testing in primary colorectal carcinoma

BACKGROUND: Anti-HER2/neu therapy is well-established in breast and gastric carcinoma. The increased understanding of this pathway led to the identification of new promising drugs in addition to trastuzumab, offering further perspectives. The role of HER2/neu in colorectal carcinoma is controversial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ingold Heppner, B, Behrens, H-M, Balschun, K, Haag, J, Krüger, S, Becker, T, Röcken, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229629/ https://www.ncbi.nlm.nih.gov/pubmed/25211663 http://dx.doi.org/10.1038/bjc.2014.483

Ejemplares similares

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma
por: Mimura, K, et al.
Publicado: (2005)

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
por: Rakovitch, E, et al.
Publicado: (2012)

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
por: Pils, D, et al.
Publicado: (2007)

Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis
por: Warneke, V S, et al.
Publicado: (2013)

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
por: de Graeff, P, et al.
Publicado: (2009)

Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
por: Warneke, V. S., et al.
Publicado: (2013)

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
por: Bellone, S, et al.
Publicado: (2012)

Impact of the coxsackievirus and adenovirus receptor on the adenoma–carcinoma sequence of colon cancer
por: Stecker, K, et al.
Publicado: (2011)

PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas
por: Aubele, M, et al.
Publicado: (2007)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma
por: Maruyama, T, et al.
Publicado: (2010)

MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer
por: Ng, E K O, et al.
Publicado: (2009)

Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression
por: Ko, Young San, et al.
Publicado: (2015)

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
por: Martin, V, et al.
Publicado: (2013)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
por: Wilson, G R, et al.
Publicado: (2006)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma
por: Kantola, T, et al.
Publicado: (2012)

Expression of osteopontin coregulators in primary colorectal cancer and associated liver metastases
por: Mole, D J, et al.
Publicado: (2011)

Detection of HER2 amplification in circulating free DNA in patients with breast cancer
por: Page, K, et al.
Publicado: (2011)

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
por: Zidan, J, et al.
Publicado: (2005)

Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia
por: Haug, U, et al.
Publicado: (2011)

Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression
por: Wyler, L, et al.
Publicado: (2014)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival
por: Hanly, A M, et al.
Publicado: (2006)

Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer
por: Murata, A, et al.
Publicado: (2013)

Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma
por: Gordziel, C, et al.
Publicado: (2013)

Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer
por: Snoeren, N, et al.
Publicado: (2013)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Low expression of γ-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype
por: Kawakami, K, et al.
Publicado: (2008)

EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer
por: Soysal, S D, et al.
Publicado: (2013)

PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness
por: Molleví, D G, et al.
Publicado: (2008)

A positive role for PEA3 in HER2-mediated breast tumour progression
por: Myers, E, et al.
Publicado: (2006)

HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder
por: Latif, Z, et al.
Publicado: (2003)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells
por: Ponnusamy, M P, et al.
Publicado: (2008)

Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer
por: Ettl, T, et al.
Publicado: (2012)

Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening
por: Tao, S, et al.
Publicado: (2012)

Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer
por: Mori, N, et al.
Publicado: (2010)

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
por: Arnould, L, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_ht6koc0dr82sompn5d195e5bs6